Top Page
NeuRizer Ltd
(Sydney:NRZ)
NeuRizer Ltd (NRZ) vs. S&P 500 (SPY)
NeuRizer Ltd Business Overview & Revenue Model
NeuRizer Ltd Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -31.45K | -45.39K | -158.53K | -179.73K | -77.68K | EBIT |
| -2.80M | -13.58M | -12.45M | -8.86M | -7.00M | EBITDA |
| -4.48M | -13.54M | -12.29M | -8.68M | -6.92M | Net Income Common Stockholders |
| -5.60M | -16.26M | -20.40M | -13.57M | -7.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 568.72K | 1.21M | 1.07M | 22.81M | 6.81M | Total Assets |
| 129.32M | 128.67M | 91.61M | 55.18M | 35.93M | Total Debt |
| 2.11M | 2.44M | 321.77K | 224.84K | 822.07K | Net Debt |
| 1.54M | 1.23M | -121.48K | -22.59M | -5.99M | Total Liabilities |
| 56.30M | 55.91M | 35.12M | 3.88M | 1.78M | Stockholders Equity |
| 73.02M | 72.75M | 56.49M | 51.30M | 34.16M |
| Cash Flow | Free Cash Flow | |||
| -6.09M | -34.32M | -16.47M | -8.27M | -1.86M | Operating Cash Flow |
| -3.56M | -9.05M | -10.23M | -4.61M | 904.92K | Investing Cash Flow |
| 826.61K | -16.11M | -27.63M | -3.14M | -2.76M | Financing Cash Flow |
| 2.09M | 25.92M | 15.49M | 23.75M | 6.38M |
NeuRizer Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $17.72B | 12.51 | 14.75% | 5.83% | 8.09% | -13.99% | |
61 Neutral | AU$19.05B | 10.27 | 7.94% | 6.05% | -7.99% | -12.27% | |
56 Neutral | $2.64B | 28.71 | 2.70% | 4.44% | 6.43% | ― | |
49 Neutral | $1.96B | -1.42 | -21.96% | 3.81% | 0.71% | -27.38% | |
44 Neutral | $239.72M | ― | -33.63% | ― | -33.27% | -10.07% | |
38 Underperform | AU$3.36M | ― | -7.69% | ― | ― | 74.00% |
NeuRizer Ltd Corporate Events
NeuRizer Ltd, along with several other companies, has been suspended from quotation on the ASX due to not lodging the required periodic report by the due date. This suspension may impact the company’s market operations and investor confidence until the report is submitted and the suspension is lifted.
NeuRizer Ltd has announced the quotation of 133,333,333 ordinary fully paid securities on the ASX, marking a significant step in their financial strategy. This move could enhance the company’s market presence and provide additional capital for growth, potentially benefiting stakeholders and strengthening its competitive positioning.
NeuRizer Ltd has announced a proposed issuance of 133,333,333 ordinary fully paid securities. The issuance is scheduled for February 20, 2025, with the intention of having these securities quoted on the ASX, subject to approval. This move could potentially enhance NeuRizer’s capital base, providing increased operational flexibility and possibly influencing its market standing.
NeuRizer Ltd has successfully completed a private share placement to raise $200,000 through the issuance of 133,333,333 new fully paid ordinary shares at $0.0015 per share. The funds raised will be used for general working capital, specifically to aid progress on the NeuRizer Urea Project, indicating an ongoing commitment to advancing its projects and potentially strengthening its market position.
NeuRizer Ltd has announced the issuance of 78,000,000 unquoted equity securities, specifically options expiring on May 29, 2028. This move is part of its employee incentive scheme, which reflects the company’s ongoing efforts to incentivize its workforce and align their goals with the company’s long-term strategies, potentially strengthening its market position.
NeuRizer Ltd, a company listed on the ASX under the code NRZ, has announced the quotation of 159,800,000 ordinary fully paid securities as of February 7, 2025, as part of previously announced transactions. This move potentially impacts the company’s market presence and operational liquidity, providing an opportunity for stakeholders to assess its financial strategy in light of these additional securities.
NeuRizer Ltd announced a new application for the quotation of 100,000,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the ticker code ‘NRZ’, dated January 30, 2025. This move signifies a strategic effort by NeuRizer Ltd to enhance its market presence and potentially increase liquidity, which could have significant implications for stakeholders and investors as the company aims to strengthen its position within the market.
NeuRizer Ltd has issued a prospectus for the offer of up to 10,000 shares at a price of $0.002 per share, intending to raise $20 before expenses. This move is primarily aimed at removing trading restrictions on shares previously issued by the company, a strategic decision that could impact the company’s market presence by potentially increasing share liquidity and investor participation.
NeuRizer Ltd has made significant progress in its NeuRizer Urea Project (NRUP) by receiving final Environmental Impact Statement guidelines from the Department of Climate Change, Energy, the Environment and Water, marking a crucial step towards project startup and approval. The reinstatement of its shares for trading and reduced operating costs further strengthen its market position, as it aims to contribute significantly to urea production, benefiting the agricultural sector in Australia and beyond.